Abstract
Disease-free survival in primary CNS lymphoma has improved with the advent of methotrexate-based pre-irradiation chemotherapy. Prolonged response durations have been noted in six of eight patients refusing radiation therapy in two of our prior series. We have treated an additional 11 patients with methotrexate-based chemotherapy without subsequent planned irradiation. Some received maintenance chemotherapy. Most have had durable responses with little or no toxicity. Prolonged responses can be maintained without radiation therapy, thus avoiding potential long-term radiation toxicity.
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Central Nervous System Neoplasms / drug therapy*
-
Central Nervous System Neoplasms / mortality
-
Central Nervous System Neoplasms / radiotherapy
-
Cranial Irradiation
-
Cyclophosphamide / administration & dosage
-
Dexamethasone / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Leucovorin / administration & dosage
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / mortality
-
Lymphoma, Non-Hodgkin / radiotherapy
-
Male
-
Methotrexate / administration & dosage
-
Middle Aged
-
Treatment Outcome
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Dexamethasone
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Methotrexate